Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30000097HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30088388HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058547HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058548HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058549HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058550HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058551HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058552HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058553HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TVIS30058554HIVENSG00000175054.16protein_codingATRNoYes545Q13535
TCGA Plot Options
Drug Information
GeneATR
DrugBank IDDB14917
Drug NameCeralasertib
Target IDBE0010060
UniProt IDQ13535
Regulation Typeinhibitor
PubMed IDs32878963
CitationsMcMullen M, Karakasis K, Loembe B, Dean E, Parr G, Oza AM: DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment. Int J Gynecol Cancer. 2020 Nov;30(11):1824-1828. doi: 10.1136/ijgc-2020-001694. Epub 2020 Sep 2.
GroupsInvestigational
Direct Classification
SMILESC[C@@H]1COCCN1C1=NC(=NC(=C1)C1(CC1)[S@](C)(=N)=O)C1=CN=CC2=C1C=CN2
Pathways
PharmGKB
ChEMBL